natgillin/translations-raw huggingface dataset:
When a person is given the vaccine, the body’s natural defence system (immune system) produces its own protection (antibodies) against the disease.
Kada osoba primi cjepivo, prirodni obrambeni sustav tijela (imunološki sustav) stvara vlastitu zaštitu (protutijela) protiv bolesti.
When a person is given the vaccine, the body’s natural defence system (immune system) produces its own protection (antibodies) against the disease.
Kada osoba primi cjepivo, prirodni tjelesni obrambeni sustav (imunološki sustav) stvoriti će svoju vlastitu zaštitu (protutijela) od bolesti.
When a person is given the vaccine, the immune system (the body’s natural defence system) will produce its own protection (antibodies) against the disease.
Kad osoba primi cjepivo, imunološki sustav (prirodni obrambeni sustav tijela) će stvoriti vlastitu zaštitu (protutijela) protiv bolesti.
When a person is given the vaccine, the immune system (the body’s natural defence system) will produce its own protection (antibodies) against the disease.
Kada osoba primi cjepivo, imunološki sustav (prirodni obrambeni sustav tijela) stvorit će svoju vlastitu zaštitu (protutijela) protiv bolesti.
When a person is given the vaccine, the immune system (the body’s natural defence system) will produce its own protection (antibodies) against the disease.
Kada osoba primi cjepivo, imunološki sustav (prirodni obrambeni sustav tijela) stvorit će vlastitu zaštitu (protutijela) protiv bolesti.
When a person is given the vaccine, the immune system (the body’s natural defence system) will produce its own protection against the influenza virus.
Kad osoba primi cjepivo, imunološki sustav (prirodni obrambeni sustav tijela) proizvest će vlastitu zaštitu protiv virusa gripe.
When a person is given the vaccine, the immune system (the body’s natural defence system) will produce its own protection against the influenza virus.
Kad osoba primi cjepivo, imunološki sustav (prirodni obrambeni sustav tijela) stvorit će vlastitu zaštitu protiv virusa gripe.
When a person is given the vaccine, the immune system (the body’s natural defence system) will produce its own protection against the influenza virus.
Kada osoba primi cjepivo, imunološki sustav (prirodni obrambeni sustav tijela) stvorit će vlastitu zaštitu protiv virusa influence.
When a person is given the vaccine, the immune system (the body’s natural defence system) will produce its own protection in the form of antibodies against the smallpox virus.
Kada neka osoba primi ovo cjepivo, imunološki sustav (prirodni obrambeni sustav u tijelu) stvorit će vlastitu zaštitu u obliku protutijela protiv virusa velikih boginja.
When a person is given the vaccine, the immune system (the body’s natural defences) will make antibodies against the measles, mumps, rubella, and varicella viruses.
Kad osoba dobije ovo cjepivo, imunološki sustav (prirodni obrambeni sustav tijela) stvori protutijela protiv virusa morbila, parotitisa, rubele i varičele.
When a person is given the vaccine, the immune system (the body’s natural defences) will make antibodies against the most commonly occurring types of rotavirus.
Kad osoba primi cjepivo, imunološki sustav (prirodna obrana organizma) će stvoriti protutijela protiv najčešćih tipova rotavirusa.
When a person is given the vaccine, the immune system (the body’s natural defense system) will produce its own protection (antibodies) against the disease.
Kad osoba primi cjepivo, imunološki sustav (prirodni obrambeni sustav tijela) stvara vlastitu zaštitu (protutijela) protiv bolesti.
When a person is given the vaccine, the immune system (the body’s natural defense system) will produce its own protection (antibodies) against the disease.
Kada osoba primi cjepivo, imunološki sustav (prirodni obrambeni sustav tijela) stvara vlastitu zaštitu (protutijela) protiv bolesti.
When a person is given the vaccine, the immune system recognises the inactivated virus as ‘foreign’ and makes antibodies against it.
Kada osoba primi cjepivo, imunosni sustav prepoznaje inaktivirani virus kao „strano tijelo” i proizvodi protutijela protiv virusa.
When a person is given the vaccine, the immune system recognises the inactivated virus as ‘foreign’ and makes antibodies against it.
Kada osoba primi cjepivo, imunosni sustav prepoznaje virus kao „strano tijelo” i proizvodi protutijela na virus.
When a person is given the vaccine, the immune system recognises the inactivated virus as ‘foreign’ and makes antibodies against it.
Nakon što osoba primi cjepivo, imunološki sustav prepoznaje virusni dio kao „strano” tijelo i stvara protutijela protiv njega.
When a person is given the vaccine, the immune system recognises the parts of the bacterium contained in the vaccine as ‘foreign’ and makes antibodies against them.
Nakon što se osoba cijepi, imunosni sustav prepoznaje dijelove bakterije sadržane u cjepivu kao „strano tijelo” te proizvodi protutijela protiv njih.
When a person is given the vaccine, the immune system recognises the parts of the bacterium contained in the vaccine as ‘foreign’ and makes antibodies against them.
Nakon što se osoba cijepi, imunosni sustav prepoznaje dijelove bakterije sadržane u cjepivu kao „strano tijelo” te proizvodi protutijela protiv tih dijelova.
When a person is given the vaccine, the immune system recognises the virus as ‘foreign’ and makes antibodies against it.
Kada osoba primi cjepivo, imunološki sustav prepoznaje virus kao „strano tijelo” i proizvodi protutijela na virus.
When a person is given the vaccine, the immune system recognises the virus as ‘foreign’ and makes antibodies against it.
Kada osoba primi cjepivo, imunosni sustav prepoznaje virus kao „strano tijelo” i proizvodi protutijela na virus.
When a person is given the vaccine, the immune system recognises the virus as ‘foreign’ and makes defences against it.
Nakon što se osoba cijepi, imunološki sustav prepoznaje virus kao „strano tijelo” te proizvodi obranu protiv virusa.
When a person is given the vaccine, the immune system recognises the virus fragments as ‘foreign’ and makes antibodies against them.
Nakon što osoba primi cjepivo, imunosni sustav prepoznaje fragmente virusa kao „strane” te protiv njih proizvodi protutijela.
When a person is given the vaccine, the immune system recognises the virus in the vaccine as ‘foreign’ and makes antibodies against them.
Kada osoba primi cjepivo, imunološki sustav prepoznaje virus u cjepivu kao „strano tijelo” i proizvodi protutijela na virus.
When a person is given the vaccine, the immune system recognises the virus parts as ‘foreign’ and makes antibodies against them.
Nakon što osoba primi cjepivo, imunosni sustav prepoznaje virusni dio kao „strano” tijelo i stvara protutijela protiv njega.
When a person is given the vaccine, the immune system recognises the weakened viruses as ‘foreign’ and makes antibodies against them.
Kada osoba primi cjepivo, imunološki sustav prepoznaje oslabljeni virus kao "strano tijelo" i proizvodi protutijela na virus.
When a pig is given the vaccine, the immune system recognises the killed viruses as ‘foreign’ and makes antibodies against them.
Nakon što svinja primi cjepivo, imunosni sustav prepoznaje ubijene viruse kao „strano” tijelo i proizvodi protutijela protiv njih.
When a radiopharmaceutical is injected, it collects in a specific organ or area of the body for a short time.
Kad se radiofarmaceutik ubrizga, na kratko vrijeme se skuplja u određenom organu ili području tijela.
When a red striped band appears in the dose indicator (see image A), this means you are nearing your last dose and you should obtain a new Genuair inhaler.
Kad se u pokazivaču doze pojavi crvena prugasta traka (pogledajte sliku A), to znači da se približavate zadnjoj dozi i da trebate novi Genuair inhalator.
When a red striped band appears in the dose indicator (see image A), this means you are nearing your last dose and you should obtain a new Genuair inhaler.
Kad se u pokazivaču doze pojavi crvena prugasta traka (vidjeti sliku A), to znači da se približavate zadnjoj dozi i da trebate novi Genuair inhalator.
When a red striped band appears in the dose indicator, this means the last dose is coming up and a new Genuair inhaler should be obtained.
Kad se u pokazivaču doze pojavi crvena prugasta traka, to znači da se približava zadnja doza i da je potrebno nabaviti novi Genuair inhalator.
When a single 100 mg dose of oral sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182 % increase in sildenafil systemic exposure (AUC).
Kada je jedna peroralna doza od 100 mg sildenafila primijenjena sa umjerenim inhibitorima CYP3A4 eritromicinom u stanju dinamičke ravnoteže (500 mg dva puta na dan tijekom 5 dana), sustavna izloženost sildenafilu (AUC) povećala se za 182%.
When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182 % increase in sildenafil systemic exposure (AUC).
Kada je jedna doza od 100 mg sildenafila primijenjena sa umjerenim inhibitorom CYP3A4 eritromicinom u stanju dinamičke ravnoteže (500 mg dva puta na dan tijekom 5 dana), sustavna izloženost sildenafilu (AUC) povećala se za 182%.
When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182 % increase in sildenafil systemic exposure (AUC).
Kod primjene jednokratne doze od 100 mg sildenafila s eritromicinom, umjerenim CYP3A4 inhibitorom, u stanju dinamičke ravnoteže (500 mg dva puta dnevno tijekom 5 dana), uočen je 182%- tni porast sustavne izloženosti sildenafilu (AUC).
When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).
Kod primjene jednokratne doze od 100 mg sildenafila s eritromicinom, umjerenim CYP3A4 inhibitorom, u stanju dinamičke ravnoteže (500 mg dva puta dnevno tijekom 5 dana), uočen je 182%- tni porast sustavne izloženosti sildenafilu (AUC).
When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily. for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).
Kod primjene jednokratne doze od 100 mg sildenafila s eritromicinom, umjerenim inhibitorom CYP3A4, u stanju dinamičke ravnoteže (500 mg dva puta dnevno tijekom 5 dana) uočen je 182%-tni porast sustavne izloženosti sildenafilu (AUC).
When a single 12-mg dose of both formulations was administered with a high fat meal, perampanel oral suspension achieves equivalent AUC0-inf and approximately 23 % lower Cmax and 2 hours delay in time to peak exposure (tmax) compared to the tablet formulation.
Kada se jedna doza od 12 mg obiju formulacija primijeni uz obrok s visokim udjelom masti, u usporedbi s formulacijom u tabletama oralna suspenzija perampanela dosegne ekvivalentnu vrijednost za AUC0-inf, približno 23% niži Cmax te vršnu izloženost (tmax) s odgodom od 2 sata.
When a single 125 mg dose of aprepitant was administered on Day 5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.
Primjena jednokratne doze aprepitanta od 125 mg 5. dan desetodnevnog režima liječenja s 400 mg na dan ketokonazola, snažnog inhibitora CYP3A,AUC aprepitanta povećao se približno 5 puta a srednje terminalno poluvrijeme aprepitanta produljilo se približno 3 puta.
When a single 125 mg dose of aprepitant was administered on Day 5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.
Primjena jednokratne doze aprepitanta od 125 mg 5. dan desetodnevnog režima liječenja s 400 mg na dan ketokonazola, snažnog inhibitora CYP3A4, AUC aprepitanta povećao se približno 5 puta, a srednje terminalno poluvrijeme aprepitanta produljilo se približno 3 puta.
When a single 125 mg dose of aprepitant was administered on Day 5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.
Primjena jednokratne doze aprepitanta od 125 mg na dan 5, desetodnevnog režima liječenja s 400 mg na dan ketokonazola, snažnog inhibitora CYP3A4, AUC aprepitanta povećao se približno 5 puta a srednje terminalno poluvrijeme aprepitanta produljilo se približno 3 puta.
When a single dose of warfarin was co-administered after repeat dosing with vemurafenib for 15 days, some patients exhibited increased warfarin exposure (mean 18%) (see section 4.4).
Kad je nakon primjene višekratnih doza vemurafeniba tijekom 15 dana istodobno primijenjena jednokratna doza varfarina, u nekih je bolesnika došlo do povećane izloženosti varfarinu (prosječno 18%) (vidjeti dio 4.4).
When a single oral dose of bosutinib (400 mg) was co-administered with multiple-oral doses of lansoprazole (60 mg) in a study of 24 healthy fasting subjects, bosutinib Cmax and AUC decreased to 54% and 74%, respectively, of the values seen when bosutinib (400 mg) was given alone.
U ispitivanju na 24 zdrava ispitanika kod istodobne primjene natašte jedne oralne doze bosutinba (400 mg) s višekratnim oralnim dozama lansoprazola (60 mg), Cmax i AUC bosutiniba smanjili su se na 54% odnosno 74% vrijednosti, u odnosu na primjenu bosutiniba (400 mg) samog.
When a sufficient number of follicles of proper size are present, the final phase of maturation of the follicles is induced by giving hCG.
Kad se ustanovi dovoljan broj folikula odgovarajuće veličine, davanjem hCG-a potiče se završna faza sazrijevanja folikula.
When Abseamed is used for autologous blood transfusion, the restrictions normally associated with this type of transfusion should be observed.
Ako se Abseamed koristi za autolognu transfuziju krvi, moraju se poštovati ograničenja u pravilu povezana s ovim tipom transfuzije.
When activity, concentrations and protein binding are taken into account, pioglitazone and metabolite M-III contribute equally to efficacy.
Kad se uzmu u obzir aktivnost, koncentracija i vezanje za proteine, pioglitazon i metabolit M-III jednako pridonose djelotvornosti.
When activity, concentrations and protein binding are taken into account, pioglitazone and metabolite M-III contribute equally to efficacy.
Kad se uzmu u obzir aktivnost, koncentracije i vezanje za proteine, pioglitazon i metabolit M-III jednako pridonose djelotvornosti.
When added to pioglitazone, the improvement was a fall of 0.47% at a dose of alogliptin of 12.5 mg, and 0.61% for alogliptin 25 mg.
Ako se doda u pioglitazon, poboljšanje je bio pad od 0,47% pri dozi alogliptina od 12,5 mg, i 0,61% za alogliptin od 25 mg.
When adding GLP-1 receptor agonists to Tresiba, it is recommended to reduce the dose of Tresiba by 20% to minimise the risk of hypoglycaemia.
Kad se agonisti GLP-1 receptora dodaju lijeku Tresiba, preporučuje se smanjiti dozu lijeka Tresiba za 20% kako bi se smanjio rizik od hipoglikemije.
When adding IT ziconotide to stable doses of IT morphine, as with the initiation of IT ziconotide monotherapy, the appearance of psychotic adverse reactions (e.g., hallucinations, paranoid reactions) or discontinuation due to increased adverse reactions may occur. (see section 4.5).
Kada se intratekalni zikonotid dodaje stabilnim dozama intratekalnog morfina mogu se, kao i kod započinjanja monoterapije intratekalnog zikonotida, pojaviti psihotične nuspojave (npr. halucinacije, paranoidne reakcije) ili povećanje nuspojava može zahtijevati prekid primjene (vidjeti dio 4.5).
When adding IT ziconotide to stable doses of IT morphine, as with the initiation of IT ziconotide monotherapy, the appearance of psychotic adverse reactions. (e.g., hallucinations, paranoid reactions) or discontinuation due to increased adverse reactions. may occur. (see section 4.5).
Kada se intratekalni zikonotid dodaje stabilnim dozama intratekalnog morfina mogu se, kao i kod započinjanja monoterapije intratekalnog zikonotida, pojaviti psihotične nuspojave (npr. halucinacije, paranoidne reakcije) ili povećanje nuspojava može zahtijevati prekid primjene (vidjeti dio 4.5).
When adding Tresiba to GLP-1 receptor agonists, the recommended daily starting dose is 10 units followed by individual dosage adjustments.
Kad se Tresiba dodaje agonistima GLP-1 receptora, preporučena dnevna početna doza je 10 jedinica nakon čega slijedi individualna prilagodba doze.
When adjusted for exposure, the adverse event rates were generally comparable with those observed during the initial study period.
Kada se prilagode za izloženost, stope štetnih događaja općenito su bile usporedive s onima uočenima u početnom razdoblju ispitivanja.
When adjusted on prognostic factors, the analyses of PFS in the subgroups of patients without or with prior cisplatin showed a HR (95% CI) = [0.51(0.31 – 0.86); p=0.0111] and a HR (95% CI) = [0.63(0.48 – 0.84); p=0.0016], respectively.
Nakon prilagodbe za prognostičke čimbenike analize PFS-a u podskupinama bolesnika bez prethodne primjene cisplatina ili s njom pokazale su omjer hazarda (HR) (95%-tni CI) = [0,51 (0,31 – 0,86); p=0,0111] odnosno omjer hazarda (HR) (95%-tni CI) = [0,63 (0,48 – 0,84); p=0,0016].
When administered 1 or 4 hours after 10 mcg lixisenatide, Cmax of paracetamol was decreased by 29% and 31% respectively and median tmax was delayed by 2.0 and 1.75 hours respectively.
Nakon primjene paracetamola 1 sat odnosno 4 sata nakon primjene 10 µg liksisenatida, Cmax paracetamola smanjio se za 29% odnosno 31%, a medijan tmax odgodio se za 2,0 odnosno 1,75 sati.
When administered 1 or 4 hours after 10-mcg lixisenatide , Cmax of paracetamol was decreased by 29% and 31% respectively and median tmax was delayed by 2.0 and 1.75 hours respectively.
Nakon primjene paracetamola 1 sat odnosno 4 sata nakon primjene 10 µg liksisenatida, Cmax paracetamola smanjio se za 29% odnosno 31%, a medijan tmax odgodio se za 2,0 odnosno 1,75 sati.
When administered concomitantly with lopinavir+ritonavir, or other ritonavir-boosted protease inhibitors, the patient’s tolerability of STAYVEER should be monitored.
Kada se STAYVEER primjenjuje u kombinaciji sa lopinavirom + ritonavirom ili nekim drugim inhibitorima proteaza pojačanih ritonavirom, treba pratiti bolesnikovu podnošljivost STAYVEERA.
When administered concomitantly with lopinavir+ritonavir, or other ritonavir-boosted protease inhibitors, the patient’s tolerability of Tracleer should be monitored.
Kada se Tracleer primjenjuje u kombinaciji sa lopinavirom + ritonavirom ili nekim drugim inhibitorima proteaza pojačanih ritonavirom, treba pratiti bolesnikovu podnošljivost Tracleera.
When administered concomitantly with lopinavir+ritonavir, or other ritonavir-boosted protease inhibitors, the patient’s tolerability of Tracleer should be monitored.
Kada se Tracleer primjenjuje u kombinaciji sa lopinavirom+ritonavirom ili nekim drugim inhibitorima proteaza pojačanih ritonavirom, treba pratiti bolesnikovu podnošljivost Tracleera.
When administered concomitantly with PREZISTA and low dose ritonavir, the patient’s tolerability of bosentan should be monitored.
Kada se bosentan daje istodobno s lijekom PREZISTA, mora se pratiti bolesnikova podnošljivost bosentana.
When administered concomitantly with PREZISTA and low dose ritonavir, the patient’s tolerability of bosentan should be monitored.
Kada se bosentan daje istodobno s PREZISTOM primijenjenim istodobno s niskom dozom ritonavira, mora se pratiti bolesnikova podnošljivost bosentana.
When administered concurrently, the following medicinal products may interact with thiazide diuretics:
Pri istodobnom liječenju, sljedeći lijekovi mogu ići u interakciju s tiazidskim diureticima:
When administered concurrently, the following medicinal products may interact with thiazide diuretics:
Pri istodobnom liječenju, sljedeći lijekovi mogu ući u interakciju s tiazidskim diureticima:
When administered concurrently, the following medicinal products may interact with thiazide diuretics:
Sljedeći lijekovi mogu ući u interakciju s tiazidnim diureticima kada se istodobno primjenjuju:
When administered in combination, the CL of nivolumab increased by 25% in the presence of anti- nivolumab antibodies.
Kod primjene kombinirane terapije, klirens nivolumaba povećao se za 25% u prisutnosti protutijela na nivolumab.
When administered in combination, the CL of nivolumab was increased by 35%, whereas there was no effect on the CL of ipilimumab.
Kod primjene kombinirane terapije, klirens nivolumaba povećao se za 35%, dok je klirens ipilimumaba ostao nepromijenjen.
When administered in combinationtherapy, patients with impaired renal function should be more carefully monitored with respect to the development of anaemia.
Bolesnike s oštećenom bubrežnom funkcijom u kojih se primjenjuje kombinirana terapija mora se pažljivije nadzirati zbog mogućnosti razvoja anemije.
When administered in conjunction with a thrombolytic (fibrin specific or non-fibrin specific) enoxaparin sodium should be given between 15 minutes before and 30 minutes after the start of fibrinolytic therapy.
Ako se primjenjuje kao zajedno s trombolitičkom terapijom (specifičnoj ili nespecifičnoj za fibrin) enoksaparin-natrij je potrebno davati u periodu 15 minuta prije i 30 minuta nakon početka fibrinolitičke terapije.
When administered in conjunction with a thrombolytic (fibrin specific or non-fibrin specific) enoxaparin sodium should be given between 15 minutes before and 30 minutes after the start of fibrinolytic therapy.
Ako se primjenjuje zajedno s trombolitičkom (fibrin specifičnoj i fibrin nespecifičnoj) terapijom, enoksaparin-natrij je potrebno davati u periodu 15 minuta prije i 30 minuta nakon početka fibrinolitičke terapije.
When administered in conjunction with a thrombolytic (fibrin specific or non-fibrin specific) enoxaparin sodium should be given between 15 minutes before and 30 minutes after the start of fibrinolytic therapy.
Ako se primjenjuje zajedno s trombolitičkom (fibrin specifičnoj i fibrin nespecifičnoj) terapijom, enoksaparinnatrij je potrebno davati u periodu od 15 minuta prije i 30 minuta nakon početka fibrinolitičke terapije.
When administered in conjunction with a thrombolytic (fibrin specific or non-fibrin specific) enoxaparin sodium should be given between 15 minutes before and 30 minutes after the start of fibrinolytic therapy.
Ako se primjenjuje zajedno s trombolitičkom terapijom (specifičnoj ili nespecifičnoj za fibrin) enoksaparin-natrij je potrebno davati u periodu 15 minuta prije i 30 minuta nakon početka fibrinolitičke terapije.
When administered in conjunction with a thrombolytic (fibrin specific or non-fibrin specific) enoxaparin sodium should be given between 15 minutes before and 30 minutes after the start of fibrinolytic therapy.
Ako se primjenjuje zajedno s trombolitičkom terapijom (specifičnoj ili nespecifičnoj za fibrin) enoksaparin-natrij je potrebno davati u periodu od 15 minuta prije i 30 minuta nakon početka fibrinolitičke terapije.
When administered in low doses (7.5 mg/m2 to 80 mg/m2 BSA), methotrexate has a mean bioavailability of approximately 70%, although considerable inter- and intra-subject variations are possible (25-100%).
Kad se metotreksat primjenjuje u niskim dozama (7,5 mg/m2 do 80 mg/m2 površine tijela), srednja vrijednost njegove bioraspoloživosti je približno 70%, iako su moguće znatne varijacije u istog i između različitih ispitanika (25-100%).
When administered intravenously, tacrolimus has been shown to have a low clearance rate.
Pokazalo se da takrolimus ima malu brzinu klirensa kad se primjenjuje intravenski.
When administered orally at a dosage of 75 mg/m2 to 7 paediatric patients, the bioavailability averaged 16% of the administered dose, with a range of 5 to 37%.
Pri peroralnoj primjeni u dozi od 75 mg/m2 u 7 pedijatrijskih bolesnika bioraspoloživost je u prosjeku iznosila 16% primijenjene doze s rasponom od 5 do 37%.